Schizophrenia Research
Volume 93, Issue 1 , Pages 109-116 , July 2007

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

  • R. Zoccali

      Affiliations

    • Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy
    • Corresponding Author InformationCorresponding author. Department of Neurosciences, Psychiatric and Anesthesiological Sciences, Policlinico Universitario Via Consolare Valeria-Messina 98125 Italy. Tel.: +39 090 22212092; fax: +39 090 695136.
    • ,
  • M.R. Muscatello

      Affiliations

    • Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy
    • ,
  • A. Bruno

      Affiliations

    • Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy
    • ,
  • R. Cambria

      Affiliations

    • Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy
    • ,
  • U. Micò

      Affiliations

    • Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy
    • ,
  • E. Spina

      Affiliations

    • Section of Pharmacology, Department of Clinical and Experimental Medicine and Pharmacology, University of Messina and IRCCS Centro Neurolesi “Bonino-Pulejo”, Messina, Italy
    • ,
  • M. Meduri

      Affiliations

    • Section of Psychiatry, Department of Neurosciences, Psychiatric and Anaesthesiological Sciences, University of Messina, Italy

Received 6 November 2006 ,Revised 12 February 2007 ,Accepted 16 February 2007.

References 

  1. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry. 1993;163(Suppl. 22):39–44
  2. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch. Gen. Psychiatry. 2000;57:270–276
  3. Andreasen N. Scale for the assessment of Negative Symptoms (SANS). Iowa: University of Iowa; 1983;
  4. Andreasen N. Scale for the assessment of Positive Symptoms (SAPS). Iowa: University of Iowa; 1984;
  5. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg GF, Sachs GS. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J. Clin. Psychiatry. 2002;63:1012–1019
  6. Chan YC, Miller KM, Shaheen N, Votolato NA, Hankins MB. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report. Schizophr. Res. 2005;78(2–3):343–345
  7. Dursun SM, Deakin JFW. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case–series outcome studies. J. Psychopharmacol. 2001;15:297–301
  8. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch. Gen. Psychiatry. 1999;56:950
  9. Gluck MR, Thomas RG, Davis KL, Haroutounian V. Increased phosphate-activated glutaminase and glutamic acid decarboxylase activities in dorsolateral prefrontal cortex of aged schizophrenics: altered glutamate and GABA metabolism in schizophrenia. Am. J. Psychiatry. 2002;159:1165–1173
  10. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 2001;158:1367–1377
  11. Halberstadt AL. The phencyclidine–glutamate model of schizophrenia. Clin. Neuropharmacol. 1995;18(3):237–249
  12. Haroutunian V, Dracheva S, Davis K. Neurobiology of glutamatergic abnormalities in schizophrenia. Clin. Neurosci. Res. 2003;3:67–76
  13. Heaton R, Chelune G, Talley J, Kay G, Curtis G. Wisconsin Card Sorting Test manual. Odessa, FL: Psychological Resources; 1993;
  14. Holzer L, Halfon O. Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient. Eur. Psychiatr. 2004;19:384–386
  15. Hurley SC. Lamotrigine update and its use in mood disorders. Ann. Pharmacother. 2002;36:860–873
  16. Ishimaru M, Kurumaji A, Toro M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol. Psychiatry. 1994;35:84–89
  17. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201–225
  18. Kalyoncu A, Mirsal H, Pektaṣ Ö, Ünsalan N, Tan D, Beyazyürek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?. Psychopharmacology. 2005;19(3):301–305
  19. Kim JS, Kornhuber HH, Scmid-Burgk W, Holzmuller B. Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 1980;20:379–382
  20. Kolivakis TT, Beauclair L, Margolese HC, Chouinard G. Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Can. J. Psychiatry. 2004;49(4):280
  21. Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine. Am. J. Psychiatry. 2001;158:1930
  22. Kremer I, Vass A, Gorelik I, Bar G, Blanaru M, Javitt DC, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry. 2004;56:441–446
  23. Labiner M. Lamotrigine and rash: scratching beneath the surface. J. Clin. Psychiatry. 2002;63:1010–1011
  24. Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology. 2005;181(3):415–436
  25. Munro J, Matthiasson P, Osborne S, Travis M, Purcell S, Cobb AM, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand. 2004;110:292–298
  26. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:799–812
  27. Premkumar, T.S., Pick, J., 2006. Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD005962. 10.1002/14651858.CD005962. pub2.
  28. Saba G, Dumortier G, Kalalou K, Benadhira R, Degrassat K, Glikman J, et al. Lamotrigine and clozapine combination in refractory schizophrenia: three cases. J. Neuropsychiatry Clin. Neurosci. 2002;14:86
  29. Simpson MD, Slater P, Deakin JF. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol. Psychiatry. 1998;44:423–427
  30. Spina E, D'Arrigo C, Migliardi G, Santoro V, Muscatello MR, Micò U, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther. Drug. Monit. 2006;28(5):599–602
  31. Spreen O, Benton AL. Neurosensory Center Comprehensive Examination For Aphasia (NCCEA). Victoria: University of Victoria Neuropsychology Laboratory; 1977;
  32. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry. 1999;32(4):148–153
  33. Tamminga CA. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry. 1999;174:12–15
  34. Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol. Psychiatry. 2005;10:27–39
  35. Thomas R, Howe V, Foister K, Keks N. Adjunctive lamotrigine in treatment-resistant schizophrenia. Int. J. Psychopharmacology. 2006;9:125–127
  36. Tiihonen J, Hallikainen T, Ryynänen O-P, Repo-Tiihonen E, Kotilainen I, Eronen M, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry. 2003;54:1241–1248
  37. Trenerry MR, Crosson B, DeBoe J, Leber WR. Stroop Neuropsychological Screening Test. Inc., Odessa FL: Psychological Assessment Resources; 1989;

PII: S0920-9964(07)00104-1

doi: 10.1016/j.schres.2007.02.009

Schizophrenia Research
Volume 93, Issue 1 , Pages 109-116 , July 2007

Article Tools